PTEN and neoplasm: This is supported in preclinical melanoma models where treatment of PTEN-deficient tumors with an agonist against a T cell costimulatory molecule, OX40 and the PI3K inhibitor, GSK2636771 [56], enhanced the anti-tumor immune response by promoting CD8+ T cell infiltration [57].